Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s40265-015-0410-1 http://scihub22266oqcxt.onion/10.1007/s40265-015-0410-1 C4464860!4464860!25985865     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Drugs 2015 ; 75 (9): 935-45 Nephropedia Template TP {{tp|p=25985865|t=2015. The New Era of Drug Therapy for Obesity: The Evidence and the Expectations |pdf=|usr=}}{{25985865}} gab.com Text The New Era of Drug Therapy for Obesity: The Evidence and the Expectations JO: Drugs http://www.kidney.de/pget.php?&tw=1&pmid=25985865 #FOAvip There is an urgent need for effective pharmacological therapies to help tackle the growing obesity epidemic and the healthcare crisis it poses. The past 3 years have seen approval of a number of novel anti-obesity drugs. The majority of these influence hypothalamic appetite pathways via dopaminergic or serotoninergic signalling. Some are combination therapies, allowing lower doses to minimize the potential for off-target effects. An alternative approach is to mimic endogenous satiety signals using long-lasting forms of peripheral appetite-suppressing hormones. There is also considerable interest in targeting thermogenesis by brown adipose tissue to increase resting energy expenditure. Obesity pharmacotherapy has seen several false dawns, but improved understanding of the pathways regulating energy balance, and better-designed trials, give many greater confidence that recently approved agents will be both efficacious and safe. Nevertheless, a number of issues from preclinical and clinical development continue to attract debate, and additional large-scale trials are still required to address areas of uncertainty. Twit Text FOAVip The New Era of Drug Therapy for Obesity: The Evidence and the Expectations ????Drugs http://www.kidney.de/pget.php?&tw=1&pmid=25985865 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25985865 #FOAvip English Wikipedia <ref>{{Cite pmid|25985865}}</ref> The New Era of Drug Therapy for Obesity: The Evidence and the Expectations #MMPMID25985865 Jones BJ; Bloom SR Drugs 2015[]; 75 (9): 935-45 PMID25985865show ga There is an urgent need for effective pharmacological therapies to help tackle the growing obesity epidemic and the healthcare crisis it poses. The past 3 years have seen approval of a number of novel anti-obesity drugs. The majority of these influence hypothalamic appetite pathways via dopaminergic or serotoninergic signalling. Some are combination therapies, allowing lower doses to minimize the potential for off-target effects. An alternative approach is to mimic endogenous satiety signals using long-lasting forms of peripheral appetite-suppressing hormones. There is also considerable interest in targeting thermogenesis by brown adipose tissue to increase resting energy expenditure. Obesity pharmacotherapy has seen several false dawns, but improved understanding of the pathways regulating energy balance, and better-designed trials, give many greater confidence that recently approved agents will be both efficacious and safe. Nevertheless, a number of issues from preclinical and clinical development continue to attract debate, and additional large-scale trials are still required to address areas of uncertainty. äThe New Era of Drug Therapy for Obesity: The Evidence and the Expectat(epmc).pdf DeepDyve Pubget Overpricing